A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

Main Inclusion Criteria: * Subject must be a healthy male or female aged 18 to 55 years at Screening * A female subject must have a negative pregnancy test at Screening and on Day -1. * A female subject of childbearing potential must agree to use an accepted method of birth control (excluding hormonal birth control methods) from Screening through 30 days after final study drug administration. * Subject must have a body mass index (BMI) from 18.5 to 32.0 kg/m2 and a weight of ≥ 50 kg at Screening. * Subject must be able to provide informed consent after risks and benefits have been explained. Subject must also be willing and able to comply with the protocol requirements. * Subject must be in general good health as determined by the Investigator based on pre-study medical, medication, and surgical history; physical examination; and clinical laboratory tests. Main Exclusion Criteria: * Subject must not have been dosed with test drug or blinded study drug in another investigational study within 30 days or 5 half-lives of the biologic activity of the test drug, whichever is longer, before the time of first study dose. * Subject must not have a history of hypersensitivity to rolapitant IV or any of its excipients or who have completed a study visit as part of a previous rolapitant study within the 6 months prior to first study drug administration (Day * Subject must not have poor venous access or consider venipuncture intolerable. * Subject must not have a history of significant complications or anxiety associated with the IV administration of medications that, in the opinion of the Investigator, could make the subject unable to complete dosing requirements. * Subject must not be pregnant or lactating.